Akero Therapeutics, Inc. (0K4.F)
| Previous Close | 10.10 |
| Open | 9.65 |
| Bid | 9.40 x N/A |
| Ask | 9.60 x N/A |
| Day's Range | 9.65 - 9.65 |
| 52 Week Range | 7.40 - 22.80 |
| Volume | |
| Avg. Volume | 15 |
| Market Cap | 432.944M |
| Beta (5Y Monthly) | 0.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis
Post hoc analysis shows potential for EFX to treat patients at highest genetic risk for progressive and advanced NASHSOUTH SAN FRANCISCO, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced the presentation of an analysis from its Phase 2a BALANCED study of efruxifermin (EFX) in patients with biopsy-confirme
- GlobeNewswire
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
$25 Million Equity Investment by Pfizer at $9.90 Per Share Term Loan Facility from Hercules Providing Up to $100 Million If Fully Drawn, Akero Cash Runway Extended One Full Year From Previously Announced Q3 2023 to Q3 2024 SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two financing
- GlobeNewswire
Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH
Presentations to highlight the association of EFX’s antifibrotic effects as scored by histology with consistent reductions in biomarkers of liver collagen synthesisSOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it will present oral and poster presentations at the Keystone Sympo
